Cancer Drug Shortages Persist at All Major U.S. Centers — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- National Comprehensive Cancer Network surveyed its 34-member alliance of leading U.S. treatment centers and found 100% are experiencing a shortage of at least one cancer medicine, with more than 20% currently short on five or more different drugs.
- 61% of cancer centers report they can still treat patients, but only by avoiding waste, rationing existing inventory, and administering the minimum suggested dosing rather than standard regimens.
- Two-thirds of centers say shortages delay treatment because staff must re-seek prior authorization from insurers for alternative therapies, adding administrative friction to clinical care.
- A majority of centers also report that shortages have disrupted ongoing clinical trials, slowing enrollment or forcing protocol changes tied to the missing drugs.
- Survey respondents describe ongoing reliance on work-around strategies rather than resolution, indicating the shortage is persistent rather than acute and episodic.
Why it matters: When 100% of leading cancer centers report at least one drug shortage and over 20% face five or more, the bottleneck is structural, not a single-supplier hiccup. Patients get minimum doses instead of standard care, insurers' prior-authorization rules compound the delay, and clinical-trial timelines slip — slowing the evidence pipeline for future oncology advances.
Ask SkimNews
